Stock listing

NASDAQ:INDP Indaptus Therapeutics, Inc. Stock

Home listing (NASDAQ) of Indaptus Therapeutics, Inc.

Follow Indaptus Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:INDP

$2.82 USD -0.47 (-14.3%)

Close on Nov 20, 2026

Past year +61.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$2.78 – $3.16 USDNov 20, 2026
Volume
239,362 sharesNov 20, 2026
Market cap
$433.2M USDAt the close on Nov 20, 2026 · price × 153.6M shares outstanding
52-week range
$0.92 – $5.96 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.10M USDMedian day 363,581 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Indaptus Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:INDP · Home$2.82 USD-0.47 (-14.3%)239,362$3.11$3.16$2.78$3.29Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:INDP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$2.82-0.47-14.3%$3.11$3.16$2.78239,362
$3.29-0.03-0.9%$3.28$3.44$3.17166,779
$3.32-0.13-3.8%$3.42$3.595$3.125278,348
$3.45+0.28+8.8%$3.17$3.55$3.095363,581
$3.17+0.02+0.6%$3.06$3.29$3.05113,195
$3.15-0.06-1.9%$3.15$3.20$3.05118,325
$3.21+0.31+10.7%$3.05$3.29$3.03264,680
$2.90-0.23-7.3%$3.15$3.19$2.66475,018
$3.13-0.19-5.7%$3.25$3.44$3.10189,797
$3.32+0.16+5.1%$3.20$3.54$3.20274,438
$3.16-0.14-4.2%$3.30$3.39$2.985204,560
$3.30+0.06+1.9%$3.25$3.35$3.105111,353
$3.24-0.26-7.4%$3.31$3.40$3.21111,967
$3.50+0.41+13.3%$3.05$3.52$3.05226,078
$3.09-0.25-7.5%$3.34$3.40$3.00241,849
$3.34+0.01+0.3%$3.37$3.438$3.3082,628
$3.33+0.025+0.8%$3.30$3.45$3.223213,464
$3.305-0.035-1.0%$3.38$3.52$3.26366,029
$3.34+0.18+5.7%$3.22$3.42$3.16352,838
$3.16+0.17+5.7%$3.00$3.22$2.865287,477
$2.99-0.17-5.4%$3.23$3.23$2.93223,700
$3.16+0.20+6.8%$2.93$3.28$2.845528,900
$2.96+0.23+8.4%$2.75$2.97$2.70218,400
$2.73+0.10+3.8%$2.55$2.796$2.47178,200
$2.63-0.22-7.7%$2.88$2.92$2.55496,200
$2.85+0.64+29.0%$2.25$2.89$2.251,324,100
$2.21-0.18-7.5%$2.34$2.40$2.025449,800
$2.39-0.05-2.0%$2.44$2.52$2.35120,000
$2.44-0.07-2.8%$2.50$2.714$2.40363,300
$2.51+0.14+5.9%$2.35$2.635$2.35467,600
$2.37+0.11+4.9%$2.37$2.53$2.29506,900
$2.26-0.33-12.7%$2.57$2.57$2.225589,200
$2.59+0.08+3.2%$2.51$2.61$2.39279,200
$2.51+0.13+5.5%$2.35$2.53$2.25361,500
$2.38+0.26+12.3%$2.11$2.416$1.94568,100
$2.12-0.18-7.8%$2.28$2.408$2.082478,500
$2.30-0.55-19.3%$2.87$2.91$2.26643,000
$2.85-0.44-13.4%$3.24$3.315$2.81589,300
$3.29-0.56-14.5%$3.78$3.834$3.125584,200
$3.85-0.15-3.7%$3.995$3.995$3.46570,900
$4.00+0.23+6.1%$3.77$4.11$3.76513,300
$3.77-0.22-5.5%$3.93$4.22$3.566624,600
$3.99+0.90+29.1%$3.10$4.06$2.951,270,100
$3.09-0.46-13.0%$3.55$3.55$2.90718,800
$3.55-0.38-9.7%$3.85$4.09$3.511,163,500
$3.93+0.72+22.4%$3.30$3.98$3.27915,800
$3.21-0.43-11.8%$3.66$3.69$2.901,200,600
$3.64+0.50+15.9%$3.40$3.695$3.051,960,500
$3.14+0.37+13.4%$2.80$3.18$2.691,378,500
$2.77+0.21+8.2%$2.70$2.94$2.461,797,900
$2.56+0.48+23.1%$2.00$2.63$1.973,181,100
$2.08+0.23+12.4%$1.92$2.39$1.895,675,600
$1.85+0.63+51.6%$1.285$1.94$1.278,463,100
$1.22+0.06+5.2%$1.20$1.235$1.17133,100
$1.16-0.01-0.9%$1.16$1.19$1.14249,900
$1.17+0.04+3.5%$1.17$1.20$1.131331,800
$1.13-0.015-1.3%$1.10$1.162$1.1073,100
$1.145+0.005+0.4%$1.14$1.17$1.09140,300
$1.14-0.02-1.7%$1.16$1.185$1.10104,000
$1.16+0.02+1.8%$1.13$1.24$1.09404,600
$1.14+0.045+4.1%$1.09$1.16$1.06206,000
$1.095-0.065-5.6%$1.15$1.18$1.09496,900
$1.16-0.13-10.1%$1.24$1.29$1.13292,700
$1.29-0.09-6.5%$1.39$1.58$1.181,134,400
$1.38+0.44+46.8%$0.942$1.42$0.9411,750,400

Splits

3 splits since 2020 · NASDAQ:INDP · every price before a split is adjusted for it

DayRatioWhat
1-for-28Consolidation
1-for-4Consolidation
1-for-20Consolidation
Ticker
NASDAQ:INDP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Indaptus Therapeutics, Inc. news

Indaptus Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
5 in the last 12 months · 63 in all · newest Nov 13, 2026 · oldest 2021
Decks
6 decks · latest September 2024

Where Indaptus Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:INDP · Home listing · This pageNASDAQUnited StatesUSD
BOATS:INDPBOATSUnited StatesUSD

Valuation

Price/book 41.9× against a median of 3.5×: the highest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$402.6M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
41.9×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.77

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Indaptus Therapeutics, Inc. · NASDAQ:INDPUS$433.2MUS$402.6Mn/an/an/a41.9×n/a0.0×1.77
CytomX Therapeutics, Inc. · NASDAQ:CTMXUS$442.5MUS$98.96Mn/a7.0×n/a1.6×−609.0%0.0×1.21
Capricor Therapeutics, Inc. · NASDAQ:CAPRUS$441.3MUS$335.9Mn/an/an/a2.1×n/a0.4×0.94
Hansa Biopharma AB · OMXSTO:HNSAUS$440.3MUS$487.4Mn/a26.3×n/an/a−406.5%n/an/a
Shanghai MicuRx Pharmaceutical Co., Ltd. Class A · SSE:688373US$438.4MUS$407.2Mn/a16.2×n/a19.4×−57.0%0.9×n/a
Clarity Pharmaceuticals Ltd. · ASX:CU6US$437.1MUS$239.0Mn/an/an/a3.5×n/a0.0×n/a
Hyundai Bioscience Co. Ltd. · KRX:048410US$435.2MUS$408.7Mn/a166×n/a5.7×−861.5%0.1×n/a
Oculis Holding AG · NASDAQ:OCSUS$434.8MUS$184.3Mn/a22,112×n/a1.8×n/a0.0×0.99
Rznomics Inc. · KRX:476830US$432.5MUS$406.0Mn/an/an/a12.5×n/a0.0×n/a
LongBio Pharma (Suzhou) Co., Ltd. Class H · HKEX:1779US$430.7MUS$402.1Mn/an/an/a20.5×n/a0.0×n/a
Ovid Therapeutics Inc. · NASDAQ:OVIDUS$429.7MUS$305.4Mn/a210×n/a2.2×n/a0.1×1.37
Median of the othersUS$436.1MUS$369.0M96.0×3.5×−507.7%0.0×1.10

Forecasts

Analysts' consensus from EODHD, read Nov 13, 2026. Not 6ix's view and not investment advice.

Price target
10.00 USD · Analysts' mean
EPS, year to Dec 2026
-6.43 · 1 analyst

Team and board

Officers

OfficerRole
Indaptus' Co-ChiefExecutive Officer and Chairman of the Board

Board

DirectorRole
Indaptus' Co-ChiefExecutive Officer and Chairman of the Board

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026+9.5%
Q2 2026Aug 13, 2026+4.9%
Q4 2025Mar 17, 2026 · After close−4.6%
Q3 2025Nov 12, 2025 · Before open+6.3%
Q2 2025Aug 13, 2025 · Before open+2.4%
Q1 2025May 14, 2025 · Before open−3.7%
Q4 2024Mar 13, 2025−4.2%
Q3 2024Nov 12, 2024 · Before open−5.0%
Q2 2024Aug 12, 2024 · Before open+0.6%
Q1 2024May 8, 2024 · Before open+1.0%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 13, 2024 · Before open−3.4%
Q3 2023Nov 6, 2023 · After close−10.1%
Q2 2023Aug 14, 2023 · Before open+7.8%
Q1 2023May 11, 2023 · Before open−9.3%
Q4 2022Mar 17, 2023 · Before open+6.3%
Q3 2022Nov 10, 2022 · After close+16.2%
Q2 2022Aug 8, 2022 · Before open−0.6%
Q1 2022May 12, 2022 · Before open+5.0%
Q4 2021Mar 21, 2022 · Before open−0.8%
Q3 2021Nov 15, 2021 · Before open−9.9%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2024)Investor deck30 slidesSeptember 2024
Investor Presentation (April 2024)Investor deck28 slidesApril 2024
Investor Presentation (January 2024)Investor deck25 slidesJanuary 2024
Investor Presentation (October 2022)Investor deck26 slidesOctober 2022
Investor Presentation (November 2021)Investor deck42 slidesNov 15, 2021
Investor Presentation (August 2021)Investor deck40 slidesAug 3, 2021

Open Decks

Financings

RaiseDate
Private placement of non-voting convertible preferred stock
Closed: US$6M raised
Buyers: David E. Lazar ($6.0 million investment for 300,000 Series AA and 700,000 Series AAA preferred shares; appointed Co-CEO and Chairman)
Dec 30, 2025
Private placement of convertible promissory notes and accompanying warrants
Tranche closed: US$5.7M raised · Warrants to purchase 200% of the conversion shares, issued following conversion of the… · Paulson Investment Company, LLC
Dealers: Paulson Investment Company, LLC (lead)
Use of proceeds: Research and development including funding a Phase 1b/2 clinical trial, working capital and general corporate purposes
Jul 1, 2025
Private placement of shares of common stock and accompanying warrants
Announced: about US$2.25M · US$1.065 a share · Warrants at US$0.94 for 60 months · Paulson Investment Company, LLC
Dealers: Paulson Investment Company, LLC (lead)
Use of proceeds: Research and development activities, working capital and general corporate purposes
Jan 13, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue000000
Cost of revenue7351.28K1.78K1.40K852854.0K859.0K829.0K701.0K
Gross profit-735-1.28K-1.78K-1.40K-852-854.0K-859.0K-829.0K-701.0K
Research and development9.34M7.25M7.62M6.32M2.52M2.66M26.7M35.4M24.3M10.1M
Selling, general and administrative10.5M8.11M8.76M8.59M5.21M944.2K542.6K
Operating income-19.8M-15.4M-16.4M-14.9M-7.73M-3.60M-34.9M-43.3M-29.4M-13.8M
Depreciation and amortization07351.28K1.78K1.40K852854.0K859.0K829.0K701.0K
EBITDA-19.8M-15.4M-16.4M-14.9M-7.73M-3.60M-34.1M-42.5M-28.6M-13.1M
Interest expense588.1K17.7K15.1K15.0K23.0K17.0K16.0K
Income before tax-20.8M-15.0M-15.4M-14.3M-7.71M-3.58M-47.0M-43.4M-28.9M-13.4M
Income tax1.72K1.70K2.45K301.65K800638.0K103.0K29.0K
Net income-20.8M-15.0M-15.4M-14.3M-7.71M-3.58M-47.6M-43.5M-28.9M-13.4M
Earnings per share, basic-21.58-44.96-1.83-1.73-1.89-1.84-3,156.85-3,126.97-3,667.26-2,614.87
Earnings per share, diluted-21.58-44.96-1.83-1.73-1.89-1.84

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents8.51M5.79M13.4M9.63M39.1M1.64M9.29M39.2M53.4M16.4M
Short-term investments016.8M0770.0K1.33M1.82M1.85M
Receivables21.1K3.49M2.03M478.0K721.0K
Current assets9.31M6.62M14.0M27.2M40.4M1.73M13.7M43.6M56.3M20.7M
Property, plant and equipment7352.02K3.80K1.35K2.20K
Total assets9.31M7.34M14.9M28.1M40.6M1.78M21.3M61.5M64.5M24.7M
Accounts payable544.1K870.2K806.0K1.38M2.54M156.0K3.51M2.85M1.85M1.15M
Current liabilities6.16M3.39M2.77M3.43M4.60M2.02M8.34M7.66M5.75M1.92M
Total debt84.2K175.1K80.5K169.3K169.3K1.34M
Total liabilities6.16M3.39M2.85M3.43M4.68M2.02M9.74M7.96M5.75M2.02M
Shareholders' equity3.15M3.94M12.1M24.6M35.9M-237.7K11.5M53.5M58.8M22.7M
Shares outstanding2.17M428.8K8.40M8.40M8.26M1.94M15.1K13.9K7.88K5.11K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-14.8M-12.3M-13.4M-13.1M-11.3M-3.32M-29.0M-39.1M-22.1M-12.0M
Capital spending-40-5-172.6K-3.85K-8.21M-921.0K-9.60M-5.00M-482.0K
Free cash flow-14.8M-12.3M-13.4M-13.3M-11.3M-3.32M-30.0M-48.7M-27.1M-12.5M
Cash from investing17.1M-16.4M447.7K447.7K-3.21M-9.30M-4.75M4.72M
Cash from financing17.5M4.75M0363.1K48.3M1.16M2.37M35.1M63.7M
Change in cash2.72M-7.58M3.74M-29.5M37.5M-2.16M-30.0M-14.1M37.0M-7.28M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 13, 2026ResultsSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 22, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 22, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 22, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 21, 2026Big-stake noticeSEC
8-K · Current reportOct 20, 2026Current reportSEC
S-8 · Registration statement for employee plansOct 5, 2026Offer documentSEC
8-K · Current reportSep 30, 2026Material contractSEC
8-K · Current reportSep 9, 2026Material contractSEC
Show 200 filings
FilingDateTypeFiled with
8-K/A · Current report, amendedSep 4, 2026Material contractSEC
8-K · Current reportSep 4, 2026Management or board changeSEC
424B5 · ProspectusSep 4, 2026Offer documentSEC
8-K · Current reportSep 1, 2026Material contractSEC
424B5 · ProspectusAug 31, 2026Offer documentSEC
424B3 · ProspectusAug 26, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 26, 2026Other filingsSEC
S-3 · Registration statementAug 17, 2026Offer documentSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveJul 20, 2026Other filingsSEC
DEF 14A · Proxy statementJul 16, 2026Meeting noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 26, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 26, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 26, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 26, 2026Big-stake noticeSEC
S-3 · Registration statementJun 26, 2026Offer documentSEC
8-K · Current reportJun 24, 2026Material contractSEC
PRE 14A · Preliminary proxy statementJun 22, 2026Meeting noticeSEC
8-K · Current reportJun 5, 2026Management or board changeSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
8-K · Current reportMay 15, 2026ResultsSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 29, 2026Big-stake noticeSEC
8-K/A · Current report, amendedApr 24, 2026Management or board changeSEC
8-K · Current reportApr 22, 2026Management or board changeSEC
3 · Initial statement of ownershipApr 20, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 6, 2026Big-stake noticeSEC
8-K · Current reportApr 3, 2026Management or board changeSEC
3 · Initial statement of ownershipApr 2, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 2, 2026Insider tradeSEC
3 · Initial statement of ownershipApr 2, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeMar 30, 2026Big-stake noticeSEC
8-K · Current reportMar 24, 2026Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 24, 2026Big-stake noticeSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
10-K · Annual reportMar 17, 2026Annual reportSEC
SCHEDULE 13D · Big-stake noticeMar 2, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 27, 2026Insider tradeSEC
8-K · Current reportFeb 27, 2026Meeting outcomeSEC
3 · Initial statement of ownershipFeb 27, 2026Insider tradeSEC
3 · Initial statement of ownershipFeb 26, 2026Insider tradeSEC
4 · Change in ownershipFeb 13, 2026Insider tradeSEC
8-K · Current reportFeb 12, 2026Material contractSEC
DEFA14A · Additional proxy materialFeb 12, 2026Meeting noticeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
4 · Change in ownershipJan 22, 2026Insider tradeSEC
DEF 14A · Proxy statementJan 21, 2026Meeting noticeSEC
8-K · Current reportJan 20, 2026Management or board changeSEC
3 · Initial statement of ownershipJan 12, 2026Insider tradeSEC
8-K · Current reportJan 8, 2026Management or board changeSEC
PRE 14A · Preliminary proxy statementJan 8, 2026Meeting noticeSEC
8-K · Current reportJan 2, 2026Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 30, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 30, 2025Big-stake noticeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 23, 2025Insider tradeSEC
3 · Initial statement of ownershipDec 23, 2025Insider tradeSEC
8-K · Current reportDec 23, 2025Material contractSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
8-K · Current reportNov 12, 2025ResultsSEC
8-K · Current reportSep 4, 2025Current reportSEC
S-1/A · Registration statement, amendedSep 3, 2025Offer documentSEC
S-1 · Registration statementSep 2, 2025Offer documentSEC
424B5 · ProspectusSep 2, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 21, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveAug 21, 2025Other filingsSEC
CORRESP · Letter to the SECAug 19, 2025Other filingsSEC
CORRESP · Letter to the SECAug 19, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 18, 2025Other filingsSEC
UPLOAD · Letter from the SECAug 18, 2025Other filingsSEC
S-3 · Registration statementAug 13, 2025Offer documentSEC
S-3 · Registration statementAug 13, 2025Offer documentSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
8-K · Current reportAug 13, 2025ResultsSEC
4 · Change in ownershipJul 29, 2025Insider tradeSEC
8-K · Current reportJul 29, 2025Meeting outcomeSEC
8-K · Current reportJul 16, 2025Current reportSEC
8-K · Current reportJul 1, 2025Material contractSEC
8-K · Current reportJun 26, 2025Current reportSEC
DEF 14A · Proxy statementJun 23, 2025Meeting noticeSEC
DJun 20, 2025Other filingsSEC
PRE 14A · Preliminary proxy statementJun 13, 2025Meeting noticeSEC
8-K · Current reportJun 13, 2025Material contractSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
4 · Change in ownershipJun 11, 2025Insider tradeSEC
8-K · Current reportJun 11, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 17, 2025Meeting noticeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
4 · Change in ownershipApr 11, 2025Insider tradeSEC
DRS · Draft registration statementMar 27, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveMar 14, 2025Other filingsSEC
8-K · Current reportMar 13, 2025ResultsSEC
POS AM · Amendment to an effective registrationMar 13, 2025Offer documentSEC
10-K · Annual reportMar 13, 2025Annual reportSEC
SCHEDULE 13G · Big-stake noticeFeb 18, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveFeb 14, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 13, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 12, 2025Other filingsSEC
S-1 · Registration statementFeb 12, 2025Offer documentSEC
8-K · Current reportFeb 12, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveFeb 12, 2025Other filingsSEC
CORRESP · Letter to the SECFeb 11, 2025Other filingsSEC
UPLOAD · Letter from the SECFeb 7, 2025Other filingsSEC
S-3 · Registration statementFeb 5, 2025Offer documentSEC
8-K · Current reportJan 31, 2025Current reportSEC
DJan 22, 2025Other filingsSEC
8-K · Current reportJan 14, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveJan 2, 2025Other filingsSEC
CORRESP · Letter to the SECDec 30, 2024Other filingsSEC
UPLOAD · Letter from the SECDec 30, 2024Other filingsSEC
S-1 · Registration statementDec 23, 2024Offer documentSEC
DDec 6, 2024Other filingsSEC
4 · Change in ownershipNov 26, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedNov 26, 2024Big-stake noticeSEC
8-K · Current reportNov 22, 2024Material contractSEC
424B5 · ProspectusNov 22, 2024Offer documentSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
8-K · Current reportOct 22, 2024Current reportSEC
SC 13D · Big-stake noticeOct 10, 2024Big-stake noticeSEC
4 · Change in ownershipOct 10, 2024Insider tradeSEC
4 · Change in ownershipOct 10, 2024Insider tradeSEC
4 · Change in ownershipOct 10, 2024Insider tradeSEC
4 · Change in ownershipOct 10, 2024Insider tradeSEC
4 · Change in ownershipOct 10, 2024Insider tradeSEC
D/AOct 4, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 23, 2024Other filingsSEC
CORRESP · Letter to the SECSep 18, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 17, 2024Other filingsSEC
S-1 · Registration statementSep 12, 2024Offer documentSEC
DAug 22, 2024Other filingsSEC
S-8 · Registration statement for employee plansAug 12, 2024Offer documentSEC
10-Q · Quarterly reportAug 12, 2024Quarterly reportSEC
8-K · Current reportAug 12, 2024ResultsSEC
4 · Change in ownershipAug 8, 2024Insider tradeSEC
8-K · Current reportAug 8, 2024Material contractSEC
424B5 · ProspectusAug 7, 2024Offer documentSEC
424B5 · ProspectusAug 6, 2024Offer documentSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
8-K · Current reportJun 7, 2024Management or board changeSEC
8-K · Current reportMay 22, 2024Current reportSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
8-K · Current reportMar 25, 2024Current reportSEC
424B5 · ProspectusMar 13, 2024Offer documentSEC
10-K · Annual reportMar 13, 2024Annual reportSEC
8-K · Current reportMar 13, 2024ResultsSEC
8-K · Current reportMar 4, 2024Current reportSEC
4 · Change in ownershipJan 23, 2024Insider tradeSEC
4 · Change in ownershipJan 23, 2024Insider tradeSEC
4 · Change in ownershipJan 23, 2024Insider tradeSEC
4 · Change in ownershipJan 23, 2024Insider tradeSEC
4 · Change in ownershipJan 23, 2024Insider tradeSEC
8-K · Current reportJan 23, 2024Current reportSEC
10-Q · Quarterly reportNov 6, 2023Quarterly reportSEC
8-K · Current reportNov 6, 2023ResultsSEC
8-K · Current reportNov 6, 2023Current reportSEC
8-K · Current reportOct 31, 2023Current reportSEC
4 · Change in ownershipAug 16, 2023Insider tradeSEC
SC 13G/A · Big-stake notice, amendedAug 16, 2023Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2023Quarterly reportSEC
8-K · Current reportAug 14, 2023ResultsSEC
8-K · Current reportAug 10, 2023Current reportSEC
4 · Change in ownershipAug 7, 2023Insider tradeSEC
3 · Initial statement of ownershipAug 7, 2023Insider tradeSEC
4 · Change in ownershipMay 30, 2023Insider tradeSEC

This page holds 200 of 345 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Indaptus Therapeutics, Inc.’s releases · as of Nov 13, 2026

Common shares
153,602,583
Fully diluted
153,602,583

Fully diluted

LineSharesAs of
Common shares153,602,583Nov 13, 2026

Warrants and options

Lot
Warrants · expire about Jun 2030

Share count over time

CountShares
Nov 13, 2026153,602,583
Sep 30, 2026133,242,324

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard201K0.13%US$463KSep 30, 2026
Geode Capital196K0.13%US$450KSep 30, 2026
Jane Street86,4840.06%US$199KSep 30, 2026
UBS83,3630.05%US$192KSep 30, 2026
Marshall Wace, LLP77,8470.05%US$179KSep 30, 2026
Millennium72,0730.05%US$166KSep 30, 2026
State Street63,8660.04%US$147KSep 30, 2026
Virtu Financial LLC34,6590.02%US$80,000Sep 30, 2026
Jump Financial, LLC27,6620.02%US$63,623Sep 30, 2026
Northern Trust27,2270.02%US$62,622Sep 30, 2026
All 20 holders
HolderSharesOf the companyValueAs of
ExodusPoint Capital Management, LP19,8840.01%US$45,733Sep 30, 2026
Qube Research & Technologies Ltd14,688<0.01%US$33,782Sep 30, 2026
Goldman Sachs14,143<0.01%US$32,529Sep 30, 2026
Barclays13,723<0.01%US$31,563Sep 30, 2026
Balyasny Asset Management L.P.12,708<0.01%US$29,228Sep 30, 2026
Morgan Stanley1,263<0.01%US$2,905Sep 30, 2026
JPMorgan28<0.01%US$80Sep 30, 2026
SBI Securities Co., Ltd.17<0.01%US$39Sep 30, 2026
Caitong International Asset Management Co., Ltd2<0.01%US$5Sep 30, 2026
Citigroup Inc1<0.01%US$2Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund17,6400.01%US$31,046May 31, 2026
Vanguard Extended Market Index Fund9,142<0.01%US$27,426Jun 30, 2026
Fidelity Series Total Market Index Fund3,929<0.01%US$6,915May 31, 2026
Fidelity Total Market Index Fund462<0.01%US$813May 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
David Natan
Other companies: Aterian, Inc. (Director · Since at least Jul 17, 2026); Quantum Cyber N.V. (Board Member · Since at least Apr 22, 2026); Sow Good Inc. (Director · Since at least Dec 31, 2025); FiEE, Inc (Director · Since at least Nov 8, 2023); Sunshine Biopharma Inc. (director · Since at least Feb 10, 2022); The Crypto Company (Chief Financial Officer · Mar 12, 2025 – Mar 12, 2025 · Past); Bio Green Med Solution, Inc. (Director · Jan 2, 2025 – Feb 26, 2025 · Past); CapForce Inc. (Director · Mar 25, 2024 – Apr 11, 2024 · Past); Vivakor, Inc. (Director · Dec 15, 2022 – Dec 15, 2022 · Past); Titan Pharmaceuticals Inc (Director · Aug 15, 2022 – Oct 25, 2023 · Past); NetBrands Corp. (Director · Feb 24, 2021 – Apr 25, 2022 · Past); PharmaNet Development Group Inc (Former EVP · Aug 3, 2007 – Dec 10, 2007 · Past)
Director · Since at least Jan 7, 2026
David Lazar
Other companies: Aterian, Inc. (Chair of the Board · Since at least Apr 27, 2026); Quantum Cyber N.V. (CEO · Since at least Feb 13, 2026); Sow Good Inc. (Chief Executive Officer and Chair of the Board · Since at least Dec 31, 2025); Kala Bio, Inc. (Chief Executive Officer, Director · Since at least Nov 23, 2025); Stablecoin Development Corporation (Chief Executive Officer, Director · Since at least Aug 19, 2025); Bio Green Med Solution, Inc. (Interim CEO · Jan 2, 2025 – Feb 26, 2025 · Past); LQR House Inc. (President, Director · Oct 15, 2024 – Apr 2, 2025 · Past); CapForce Inc. (Chief Executive Officer, Director · Mar 25, 2024 – Jul 30, 2024 · Past); FiEE, Inc (Director · Dec 29, 2023 – Feb 18, 2025 · Past); Titan Pharmaceuticals Inc (Chief Executive Officer, Director · Jan 24, 2023 – Jul 26, 2023 · Past)
Director · Since at least Dec 22, 2025
William B Hayes
Other companies: Builders FirstSource, Inc. (Director · Since at least Oct 14, 2019); Intec Pharma Ltd (Director · Jan 1, 2019 – Jul 15, 2020 · Past); Patheon N.V. (Director · Jul 20, 2016 – Aug 29, 2017 · Past); Labcorp Holdings Inc. (Chief Financial Officer, EVP · Feb 9, 2012 – Jun 6, 2014 · Past); Orchid Cellmark Inc (EVP and Treasurer, Director · Dec 9, 2011 – Dec 9, 2011 · Past)
Director · Since at least Jul 23, 2021
Avraham Ben-Tzvi
Other companies: Aterian, Inc. (Director · Since at least Jul 17, 2026); Quantum Cyber N.V. (Director · Since at least Apr 22, 2026); Black Titan Corp (Director · Since at least Oct 1, 2025); Titan Pharmaceuticals Inc (Director · Since at least Oct 1, 2025)
Director · Since at least Dec 22, 2025
Matthew Charles McMurdo
Other companies: CapForce Inc. (Director · Mar 25, 2024 – Apr 11, 2024 · Past); FiEE, Inc (Director · Dec 29, 2023 – Sep 26, 2024 · Past); Titan Pharmaceuticals Inc (Director · Aug 15, 2022 – Oct 25, 2023 · Past)
Director · Since at least Feb 26, 2026
Hila Karah
Other companies: DarioHealth Corp. (Board Member · Since at least Mar 3, 2016); Intec Pharma Ltd (Director · Jan 1, 2019 – Jul 15, 2020 · Past)
Director · Since at least Jul 23, 2021
Roger Pomerantz
Other companies: Enlivex Ltd. (Director · Since at least Mar 18, 2026); Viracta Therapeutics Inc (Director · May 25, 2022 – Nov 25, 2024 · Past)
Director · Since at least Sep 30, 2022
Walt Addison Linscott
Other companies: Intec Pharma Ltd (Chief Business Officer · Jan 1, 2019 – Sep 16, 2020 · Past); Cocrystal Pharma, Inc. (GENERAL COUNSEL AND SECRETARY · Jul 21, 2015 – Jul 21, 2015 · Past)
Chief Operating Officer · Since at least Jul 23, 2021
Jeffrey A. Meckler
Other companies: Travere Therapeutics, Inc. (Director · Since at least May 14, 2021)
Co-Chief Executive Officer, Director · Since at least Jul 23, 2021
Jerome D. Jabbour
Other companies: Matinas BioPharma Holdings, Inc. (Co-founder, Chairman & Chief Executive Officer · Since at least Mar 22, 2018)
Director · Since at least Feb 26, 2026
All 18 people
PersonSeat
Junyi Dai
Other companies: Mega Matrix Inc. (Director · May 10, 2024 – May 10, 2024 · Past)
Chief Executive Officer · Since at least Mar 23, 2026
Nir Sassi
Other companies: Intec Pharma Ltd (Chief Financial Officer · Jan 1, 2019 – Sep 16, 2020 · Past)
Chief Financial Officer · Since at least Jul 23, 2021
Robert Martell
Other companies: Curis, Inc. (Head of Research & Development · Sep 14, 2011 – Jan 20, 2023 · Past)
Director · Since at least Feb 13, 2023
Boyan Vesselinov LitchevChief Medical Officer · Jan 31, 2022 – Feb 1, 2022 · Past
Indaptus' Co-ChiefExecutive Officer and Chairman of the Board · Since at least Dec 30, 2025
Mark John GilbertDirector · Since at least Jun 10, 2025
Michael James NewmanCSO and Director, Director · Since at least Dec 22, 2025
Qinglai LuDirector · Since at least Apr 8, 2026

Open People

Log in to ask 6ix AI your own questions about Indaptus Therapeutics, Inc.